Cargando…

Effects of dopamine on reinforcement learning in Parkinson’s disease depend on motor phenotype

Parkinson’s disease is clinically defined by bradykinesia, along with rigidity and tremor. However, the severity of these motor signs is greatly variable between individuals, particularly the presence or absence of tremor. This variability in tremor relates to variation in cognitive/motivational imp...

Descripción completa

Detalles Bibliográficos
Autores principales: van Nuland, Annelies J, Helmich, Rick C, Dirkx, Michiel F, Zach, Heidemarie, Toni, Ivan, Cools, Roshan, den Ouden, Hanneke E M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719026/
https://www.ncbi.nlm.nih.gov/pubmed/33147621
http://dx.doi.org/10.1093/brain/awaa335
_version_ 1783619608274534400
author van Nuland, Annelies J
Helmich, Rick C
Dirkx, Michiel F
Zach, Heidemarie
Toni, Ivan
Cools, Roshan
den Ouden, Hanneke E M
author_facet van Nuland, Annelies J
Helmich, Rick C
Dirkx, Michiel F
Zach, Heidemarie
Toni, Ivan
Cools, Roshan
den Ouden, Hanneke E M
author_sort van Nuland, Annelies J
collection PubMed
description Parkinson’s disease is clinically defined by bradykinesia, along with rigidity and tremor. However, the severity of these motor signs is greatly variable between individuals, particularly the presence or absence of tremor. This variability in tremor relates to variation in cognitive/motivational impairment, as well as the spatial distribution of neurodegeneration in the midbrain and dopamine depletion in the striatum. Here we ask whether interindividual heterogeneity in tremor symptoms could account for the puzzlingly large variability in the effects of dopaminergic medication on reinforcement learning, a fundamental cognitive function known to rely on dopamine. Given that tremor-dominant and non-tremor Parkinson’s disease patients have different dopaminergic phenotypes, we hypothesized that effects of dopaminergic medication on reinforcement learning differ between tremor-dominant and non-tremor patients. Forty-three tremor-dominant and 20 non-tremor patients with Parkinson’s disease were recruited to be tested both OFF and ON dopaminergic medication (200/50 mg levodopa-benserazide), while 22 age-matched control subjects were recruited to be tested twice OFF medication. Participants performed a reinforcement learning task designed to dissociate effects on learning rate from effects on motivational choice (i.e. the tendency to ‘Go/NoGo’ in the face of reward/threat of punishment). In non-tremor patients, dopaminergic medication improved reward-based choice, replicating previous studies. In contrast, in tremor-dominant patients, dopaminergic medication improved learning from punishment. Formal modelling showed divergent computational effects of dopaminergic medication as a function of Parkinson’s disease motor phenotype, with a modulation of motivational choice bias and learning rate in non-tremor and tremor patients, respectively. This finding establishes a novel cognitive/motivational difference between tremor and non-tremor Parkinson’s disease patients, and highlights the importance of considering motor phenotype in future work.
format Online
Article
Text
id pubmed-7719026
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77190262020-12-09 Effects of dopamine on reinforcement learning in Parkinson’s disease depend on motor phenotype van Nuland, Annelies J Helmich, Rick C Dirkx, Michiel F Zach, Heidemarie Toni, Ivan Cools, Roshan den Ouden, Hanneke E M Brain Original Articles Parkinson’s disease is clinically defined by bradykinesia, along with rigidity and tremor. However, the severity of these motor signs is greatly variable between individuals, particularly the presence or absence of tremor. This variability in tremor relates to variation in cognitive/motivational impairment, as well as the spatial distribution of neurodegeneration in the midbrain and dopamine depletion in the striatum. Here we ask whether interindividual heterogeneity in tremor symptoms could account for the puzzlingly large variability in the effects of dopaminergic medication on reinforcement learning, a fundamental cognitive function known to rely on dopamine. Given that tremor-dominant and non-tremor Parkinson’s disease patients have different dopaminergic phenotypes, we hypothesized that effects of dopaminergic medication on reinforcement learning differ between tremor-dominant and non-tremor patients. Forty-three tremor-dominant and 20 non-tremor patients with Parkinson’s disease were recruited to be tested both OFF and ON dopaminergic medication (200/50 mg levodopa-benserazide), while 22 age-matched control subjects were recruited to be tested twice OFF medication. Participants performed a reinforcement learning task designed to dissociate effects on learning rate from effects on motivational choice (i.e. the tendency to ‘Go/NoGo’ in the face of reward/threat of punishment). In non-tremor patients, dopaminergic medication improved reward-based choice, replicating previous studies. In contrast, in tremor-dominant patients, dopaminergic medication improved learning from punishment. Formal modelling showed divergent computational effects of dopaminergic medication as a function of Parkinson’s disease motor phenotype, with a modulation of motivational choice bias and learning rate in non-tremor and tremor patients, respectively. This finding establishes a novel cognitive/motivational difference between tremor and non-tremor Parkinson’s disease patients, and highlights the importance of considering motor phenotype in future work. Oxford University Press 2020-11-05 /pmc/articles/PMC7719026/ /pubmed/33147621 http://dx.doi.org/10.1093/brain/awaa335 Text en © The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Original Articles
van Nuland, Annelies J
Helmich, Rick C
Dirkx, Michiel F
Zach, Heidemarie
Toni, Ivan
Cools, Roshan
den Ouden, Hanneke E M
Effects of dopamine on reinforcement learning in Parkinson’s disease depend on motor phenotype
title Effects of dopamine on reinforcement learning in Parkinson’s disease depend on motor phenotype
title_full Effects of dopamine on reinforcement learning in Parkinson’s disease depend on motor phenotype
title_fullStr Effects of dopamine on reinforcement learning in Parkinson’s disease depend on motor phenotype
title_full_unstemmed Effects of dopamine on reinforcement learning in Parkinson’s disease depend on motor phenotype
title_short Effects of dopamine on reinforcement learning in Parkinson’s disease depend on motor phenotype
title_sort effects of dopamine on reinforcement learning in parkinson’s disease depend on motor phenotype
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719026/
https://www.ncbi.nlm.nih.gov/pubmed/33147621
http://dx.doi.org/10.1093/brain/awaa335
work_keys_str_mv AT vannulandanneliesj effectsofdopamineonreinforcementlearninginparkinsonsdiseasedependonmotorphenotype
AT helmichrickc effectsofdopamineonreinforcementlearninginparkinsonsdiseasedependonmotorphenotype
AT dirkxmichielf effectsofdopamineonreinforcementlearninginparkinsonsdiseasedependonmotorphenotype
AT zachheidemarie effectsofdopamineonreinforcementlearninginparkinsonsdiseasedependonmotorphenotype
AT toniivan effectsofdopamineonreinforcementlearninginparkinsonsdiseasedependonmotorphenotype
AT coolsroshan effectsofdopamineonreinforcementlearninginparkinsonsdiseasedependonmotorphenotype
AT denoudenhannekeem effectsofdopamineonreinforcementlearninginparkinsonsdiseasedependonmotorphenotype